16.1 C
Delhi
Wednesday, March 4, 2026

Tag: FDA RMAT designation

Intellia Pauses CRISPR Trial After Patient Liver Reaction

Intellia Therapeutics halts Phase 3 gene therapy trials after participant develops severe liver complications. Learn about the safety pause and implications.